Skip to main content

Table 1 Relationship between expression levels of miR-133b and clinicopathologic parameters in 140 GC cases

From: MiR-133b is frequently decreased in gastric cancer and its overexpression reduces the metastatic potential of gastric cancer cells

Clinicopathologic parameters miR-133b expression p-value
Low (n = 46) Middle (n = 47) High (n =47)
Age (years)     
≤60 20 16 28 *0.04
>60 26 31 19  
Gender     
Male 39 30 31 0.05
Female 7 17 16  
Differentiation     
High, middle 14 17 9 0.18
Low 32 30 38  
Location     
Distal third 28 23 24 0.63
Middle third 13 14 16  
Proximal third 5 10 7  
Local invasion     
T1 5 6 1 0.16
T2 14 5 12  
T3 10 14 13  
T4 17 22 21  
Lymph node metastasis     
N0 7 12 13 *0.03
N1 7 7 11  
N2 14 19 19  
N3 18 9 4  
TNM stage     
I, II 22 20 22 0.86
III, IV 24 27 25  
  1. A total of 140 cases were stratified into three groups based on relative miR-133b expression (tumor/non-tumor ratio) using tertiles: miR-133b low expression (tumor/non-tumor ratio < 0.24, n = 46), miR-133b moderate expression (tumor/non-tumor ratio 0.24–0.87, n = 47) and miR-133b high expression (tumor/non-tumor ratio > 0.87, n = 47). The relationship between the miR-133b expression levels and clinicopathologic parameters was analyzed using the Pearson Chi-square test. *, p <0.05.